Safety and effectiveness of tolvaptan for fluid management after pediatric cardiovascular surgery.

about

Safety and effectiveness of tolvaptan for fluid management after pediatric cardiovascular surgery.

Item

http://www.wikidata.org/entity/Q38710306

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Safety and effectiveness of to ...... iatric cardiovascular surgery.

@en

type

Item

label

Safety and effectiveness of to ...... iatric cardiovascular surgery.

@en

prefLabel

Safety and effectiveness of to ...... iatric cardiovascular surgery.

@en

P1476

Safety and effectiveness of to ...... diatric cardiovascular surgery

@en

P2093

Hiroshi Masuhara

http://www.w3.org/2001/XMLSchema#string

Noritsugu Shiono

http://www.w3.org/2001/XMLSchema#string

Takeshiro Fujii

http://www.w3.org/2001/XMLSchema#string

Tsukasa Ozawa

http://www.w3.org/2001/XMLSchema#string

Yoshinori Watanabe

http://www.w3.org/2001/XMLSchema#string

P2860

BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy

Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.

Non-peptide arginine-vasopressin antagonists: the vaptans.

Predictive factors for responders to tolvaptan in fluid management after cardiovascular surgery.

Efficacy and safety of tolvaptan for pediatric patients with congestive heart failure. Multicenter survey in the working group of the Japanese Society of PEdiatric Circulation and Hemodynamics (J-SPECH).

Guidelines for treatment of acute heart failure (JCS 2011).

Syndrome of inappropriate secretion of antidiuretic hormone associated with angiotensin-converting enzyme inhibitor administration.

The efficacy of tolvaptan in the perioperative management of chronic kidney disease patients undergoing open-heart surgery.

Effects of tolvaptan in the early postoperative stage after heart valve surgery: results of the STAR (Study of Tolvaptan for fluid retention AfteR valve surgery) trial.

Effects of short-term administration of tolvaptan after open heart surgery.

P2888

s11748-017-0798-5

P304

622-626

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11748-017-0798-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Yuzo Katayama

P577

2017-06-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28647800

http://www.w3.org/2001/XMLSchema#string

P921

cardiac surgery